Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Risk factors for rare diseases can be risky to define: PML and natalizumab.
Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense "black holes": a post hoc magnetic resonance imaging analysis.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.
ATX-MS-1467, An Immunotolerizing Agent, Halts Disease Progression and Reduces CNS Inflammation in Rodent Models of Multiple Sclerosis (P1.216)
Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
Clinical profile of malay children with optic neuritis.
The history of the oxazaphosphorine cytostatics.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Physiopathological Roles of p2x Receptors in the Central Nervous System.
Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1.
Yield of emergent neuroimaging among children presenting with a first complex febrile seizure.
Multigate Quality Doppler Profiles and Morphological/Hemodynamic Alterations in Multiple Sclerosis Patients.
Considering the influence of stimulation parameters on the effect of conventional and high-definition transcranial direct current stimulation.
Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple Sclerosis.
Peripheral and Central Nervous System Drugs Advisory Committee Meeting: Alemtuzumab (BLA 103948\5139) Background Package
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.

Pages